Delayed emergence of bovine leukemia virus after vaccination with a protective cytotoxic T cell-based vaccine.
In a previous study eight MHC class I-matched sheep were vaccinated with a minimal cytotoxic T lymphocyte (CTL) peptide epitope vaccine and were challenged with the retrovirus, bovine leukemia virus (BLV). Half the vaccinated animals remained PCR negative after challenge, whereas the remaining half and the placebo group became PCR positive within 4 weeks postchallenge (Hislop AD, Good MF, Mateo L, Gardner J, Gatei MH, Daniel RCW, Meyers BV, Lavin MF, and Suhrbier A: Nat Med 1998;4:1193). Here we show that neither epitope mutations nor processing differences explained why half the peptide-vaccinated animals failed to resist the BLV challenge. However, in these animals the development of BLV-induced lymphosarcomas was significantly delayed compared with the placebo group, suggesting a role for CTLs in preventing retrovirus-induced cancers. Importantly, two of the initially protected animals become PCR positive after approximately 1.5 years, indicating extended suppression but not elimination of challenge virus by vaccine-induced CTLs. The late emergence of virus could not be explained by epitope escape mutations or the loss of memory CTL responses. We speculate that high levels of effector CTL may be needed to protect animals from a postchallenge viremia and maintenance of such effector CTLs, rather than memory CTLs, may be required to prevent subsequent emergence of virus from latent pools.
Mateo
L
L
Australian National Centre for International and Tropical Health and Nutrition, Queensland Institute of Medical Research and the University of Queensland, Post Office Royal Brisbane Hospital, Queensland 4029, Australia.
Gardner
J
J
Suhrbier
A
A
D000818:Animals; D002417:Cattle; D018450:Disease Progression; D016583:Enzootic Bovine Leukosis / Q000276:immunology / Q000517:prevention & control / Q000821:virology*; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D001909:Leukemia Virus, Bovine / Q000276:immunology* / Q000302:isolation & purification; D016296:Mutagenesis; D016133:Polymerase Chain Reaction / Q000379:methods; D012756:Sheep; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D013997:Time Factors; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
D018984:Epitopes, T-Lymphocyte; D014614:Vaccines, Synthetic; D014765:Viral Vaccines